This page shows the publications co-authored by Elliot Israel and Joshua Boyce.
A trial of type 12 purinergic (P2Y12) receptor inhibition with prasugrel identifies a potentially distinct endotype of patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2019 01; 143(1):316-324.e7.
Novel Treatments for Airway Disease. N Engl J Med. 2017 08 10; 377(6):597.
KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma. N Engl J Med. 2017 05 18; 376(20):1911-1920.
LTC4 synthase polymorphism modifies efficacy of botanical seed oil combination in asthma. Springerplus. 2014; 3:661.
Systems Approaches to Treatment Response to Imatinib in Severe Asthma: A Pilot Study. J Pers Med. 2021 Mar 25; 11(4).
Unique Effect of Aspirin Therapy on Biomarkers in Aspirin-exacerbated Respiratory Disease. A Prospective Trial. Am J Respir Crit Care Med. 2019 09 15; 200(6):704-711.
Plasma tryptase elevation during aspirin-induced reactions in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2019 02; 143(2):799-803.e2.
Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2016 05; 137(5):1566-1576.e5.
Impact of botanical oils on polyunsaturated fatty acid metabolism and leukotriene generation in mild asthmatics. Lipids Health Dis. 2013 Oct 02; 12:141.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.